Healthcare / BiotechnologyTaiwan
$160.00
+1.50 (+0.95%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 22%
FCF escenarios
weak_data · normalized FCF $34.3M · quality 55.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
37/100
D
Piotroski
5/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$10.6B
P/E
500.0x
↑EV/EBITDA
198.0x
↑ROE
1.8%
↑Gross Margin
46.2%
↓Debt/Equity
0.04
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-5.1%
FCF CAGR
-9.9%
FCF margin
5.0%
FCF / Net income
1.79x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $685.5M · net income $19.2M · FCF $34.3M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $685.5M | $685.5M | $666.5M | $969.6M | $802.4M |
| Net Income | $19.2M | $19.2M | $21.0M | $18.6M | $18.3M |
| EBITDA | $46.7M | $46.7M | $50.5M | $46.7M | $45.5M |
| EPS | — | — | 0.36 | 0.35 | 0.37 |
| Gross Margin | 46.2% | 46.2% | 49.1% | 49.5% | 55.9% |
| Operating Margin | 2.6% | 2.6% | 1.5% | 2.3% | 3.2% |
| Net Margin | 2.8% | 2.8% | 3.2% | 1.9% | 2.3% |
| Balance Sheet | |||||
| Debt/Equity | 0.04 | 0.04 | 0.05 | 0.12 | 0.32 |
| Current Ratio | 6.49 | 6.49 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $34.3M | $34.3M | $159.1M | $-42.4M | $47.0M |
| Returns | |||||
| ROE | 1.8% | 1.8% | 2.0% | 1.8% | 3.4% |
| Valuation | |||||
| P/E | 500.00 | 500.00 | — | — | — |
| EV/EBITDA | 198.03 | 198.03 | — | — | — |
| P/B | 8.95 | 8.95 | — | — | — |
| Growth & Yield | |||||
| Revenue Growth | 2.8% | 2.8% | -31.3% | 20.8% | — |
| EPS Growth | — | — | 2.9% | -5.4% | — |
| Dividend Yield | 0.2% | 0.2% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+2.8%
Start / end P/E
n/dx → n/dx
EPS bridge
0.36 → n/d
Residual
+2.6%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.